£495.00

The 2013-2018 Outlook for Renal Cell Carcinoma (RCC) Drugs in the United States

Econometrics

Price data last checked 19 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 72 days · 72 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 72 days • 1 price levels

Days at Price

Price Analysis

Most common price: £495 (72 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 72 days

Description

This econometric study covers the latent demand outlook for renal cell carcinoma (RCC) drugs across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,700 cities in the United States. For each city in question, the percent share the city is of it's state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for renal cell carcinoma (RCC) drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in the United States). This study gives, however, my estimates for the latent demand, or the P.I.E., for renal cell carcinoma (RCC) drugs in the United States. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of the United States. For each state, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business.

Product Specifications

Format: paperback
ASIN: B00E0XFF6M
Category: Books > Subjects > Business, Finance & Law > Economics > Econometrics
Domain: Amazon UK
Release Date: 17 July 2013
Listed Since: 23 July 2013

The 2013-2018 Outlook for Renal Cell Carcinoma (RCC) Drugs in the United States

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Kidney Cancer Drugs in the United States

The 2013-2018 Outlook for Non-Small Cell Lung Cancer Therapeutics in Africa & the Middle East

Clear Cell Renal Cell Carcinoma 2021-2022

The 2023-2028 Outlook for End Stage Renal Diseases in the United States

The 2023-2028 Outlook for Kidney /Renal Function Tests in the United States

The 2023-2028 Outlook for Cancer Screenings in the United States

Renal Cell Carcinoma: Research and Treatments

The 2013-2018 Outlook for Non-Small Cell Lung Cancer Therapeutics in Europe

The 2023-2028 Outlook for Kidney /Renal Function Tests in India

The 2013-2018 Outlook for Non-Small Cell Lung Cancer Therapeutics in Asia

The 2023-2028 Outlook for Cancer Supportive Care Drugs in the United States

Renal Cell Carcinoma

The 2023-2028 Outlook for Cancer Supportive Care Drugs in China

The 2023-2028 Outlook for Cancer Screenings in China

Renal Cancer: Old and New Paradigms, An Issue of Urologic Clinics: Volume 50-2 (The Clinics: Surgery, Volume 50-2)

The 2023-2028 Outlook for Cancer Supportive Care in the United States

The 2023-2028 Outlook for Kidney /Renal Function Tests in China

Kidney cancer (renal cell carcinoma): A survival guide for patients

The 2023-2028 Outlook for Cancer Supportive Care Drugs in India

The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Africa, Europe & the Middle East

The 2023-2028 Outlook for Cancer Supportive Care Drugs in Japan

The 2023-2028 Outlook for Cancer Screenings in Japan

The 2023-2028 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States

The 2023-2028 Outlook for Kidney /Renal Function Tests in Japan